1. Use of Artificial Networks in Clinical Trials: A Pilot Study to Predict Responsiveness to Donepezil in Alzheimer's Disease.
- Author
-
Mecocci, Patrizia, Grossi, Enzo, Buscema, Massimo, Intraligi, Marco, Savarè, Rita, Rinaldi, Patrizia, Cherubini, Antonio, and Senin, Umberto
- Subjects
BIOLOGICAL neural networks ,ALZHEIMER'S disease - Abstract
OBJECTIVES: To evaluate the accuracy of artificial neural networks compared with discriminant analysis in classifying positive and negative response to the cholinesterase inhibitor donepezil in a group of Alzheimer's disease (AD) patients. DESIGN: Convenience sample. SETTING: Patients with mild to moderate AD consecutively admitted to a geriatric day hospital and treated with donepezil 5 mg/day. PARTICIPANTS: Sixty-one older patients of both sexes with AD. MEASUREMENTS: Accuracy in detecting subjects sensitive (responders) or not (nonresponders) to 3-month therapy with ANNs. The criterion standard for evaluation of efficacy was the scores of Alzheimer's Disease Assessment Scale—Cognitive portion and Clinician's Interview Based Impression of Change—plus scales. RESULTS: ANNs were more effective in discriminating between responders and nonresponders than other advanced statistical methods, particularly linear discriminant analysis. The total accuracy in predicting the outcome was 92.59%. CONCLUSIONS: ANNs appear to be a useful tool in detecting patient responsiveness to pharmacological treatment in AD. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF